New Phase III Study of Nintedanib in People with Systemic Sclerosis and Lung Fibrosis Launched

• First person enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS)   study investigating nintedanib in people with systemic sclerosis who also develop interstitial lung   disease (SSc-ILD) • Phase III trial is now open for recruitment • After demonstrating that nintedanib slows disease progression in idiopathic pulmonary fibrosis,   Boehringer Ingelheim is expanding its research with nintedanib into other serious fibrotic lung   conditions that arise in association with rare diseases like systemic sclerosis
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news